Lumeon secures $28M in funding to accelerate growth in the US market - Gilde Healthcare

Lumeon secures $28M in funding to accelerate growth in the US market

December 4, 2018

Utrecht (The Netherlands), Boston (United States) – Lumeon, the digital health scale-up in Care Pathway Management (CPM), today announced the closure of a $28M investment. The financing allows Lumeon to expand its U.S. team and Boston headquarters, scale commercial operations and accelerate customer deployments in the region.
 
Along with LSP as lead investor, the finance was provided by MTIP and current investors Gilde, Amadeus Capital Partners, IPF Partners and Cedars-Sinai Medical Center.

 

About Lumeon
Lumeon enables healthcare organizations to orchestrate and automate systems and processes, bringing situational awareness to care operations to deliver high performance, team-centered healthcare. The industry-leading Lumeon Care Pathway Management (CPM) platform and suite of solutions empower health organizations to take control of their end-to-end care delivery model and maximize the use of resources. By iteratively designing and deploying efficient pathways, organizations reduce cost and minimize unwarranted variation, while flexibly adapting to emerging needs.
 
With headquarters in the USA and Europe, Lumeon serves some of the largest health enterprises across the globe, managing over six million patients on its platform. Find out more at www.lumeon.com.
 
About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two business lines: a venture & growth capital fund and a private equity fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare services companies with a focus on the Benelux and DACH-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare company CatalYm announces leadership changes to accelerate visugromab late-stage clinical development

Gilde Healthcare company CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced changes to its executive leadership team to support its next stage of growth. The appointments of Clinton Musil as Chief...
September 15, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor...
September 10, 2025

Gilde Healthcare appoints Dr. Christian Stark as Group CEO of its globally operating medical technology group

The medical technology group, which includes two manufacturers of surgical instruments in the Tuttlingen region, Koscher & Würtz and Christian Diener, has appointed Dr. Christian Stark as Chief Executive Officer (CEO) with effect from September...
September 3, 2025